Table 1 Origin, resistance properties and molecular typing of OXA-48 β-Lactamase Escherichia coli isolates from a Spanish hospital.

Isolate	Year of isolation	Patient Sex^a/age^b	Origin^c	Sample	Resistance phenotype^d/genes^e	ERT/IPM/MER MIC	Serotype	MLST^f	fimH allele	Virotype^g	Phylogroup
Ec-HUCA 1^h	2012	F/46	GSU	Surgical wound	AMP, AMC, ETP, IPM^I, ERYⁱ, NAL, TET/bla _TEM-1b, bla _OXA-48, mph (A), gyrA-S83L, tet (B)	2/2/0.19	O16:H5	ST131/PST506	H41	nt	B2
Ec-HUCA 2^h	2012	M/57	ICU	Surgical wound	AMP, AMC, CTX, ETP, IMP^I, [AMK^I, GEN, TOB], KAN, STR, ERYⁱ, SUL, TMP, SXT,TET/bla _TEM-1b, bla _OXA-30, bla _CTX-M-15, bla _OXA-48, aph (3′)-Ia, aadA1, strB, mph (A), sul1, dfrA5, tet (A)	2/2/0.125	O9:H25	ST58/PST24	H27	na	B1
Ec-HUCA 3^h	2012	M/68	RU	Urine	AMP, AMC, ETP, IMP^I/ampC2, ampH, bla _OXA-48	2/2/0.38	O25:H5	ST83/PST207	H21	na	B2
Ec-HUCA 4	2014	M/45	ICU	Surgical wound	AMP, AMC, FOX, ETP, IPM^I, MER, CHL, NAL, SUL, TMP, SXT, TET/bla _TEM-1c, bla _OXA-48, cmlA1, gyrA-S83L, sul3, tet (A)	4/2/3	O25:H4	ST131/PST9	H22	D5	B2
Ec-HUCA 5	2015	F/79	PCC	Urine	AMP, AMC, FOX, CTX, ETP, NAL, CIP, SXT/bla _CTX-M-15, bla _OXA-48, gyrA-S83L + D87N, parC-S80I + E84V, folA-W30R	2/0.5/0.38	O25:H4	ST131/PST43	H30	E	B2
Ec-HUCA 6	2015	M/80	EU	Urine	AMP, AMC, FOX, CTX, ETP, CHL, NAL, CIP, SXT, TMP/bla _CTX-M-15, bla _OXA-48, gyrA-S83L + D87N, parC-S80I + E84V, qnrS1, dfrA14	2/0.5/0.38	O25:H4	ST131/PST43	H30	E	B2
Ec-HUCA 7	2015	F/86	GU	Urine	AMP, AMC, FOX, CTX, ETP, CHL, NAL, CIP, SXT, TMP/bla _CTX-M-15, bla _OXA-48, gyrA-S83L + D87N, parC-S80I + E84V; parE-I529L, qnrS1, dfrA14	2/0.5/0.38	O25:H4	ST131/PST43	H30	E	B2

^aF, female; M, male. ^byears old. ^cGSU, general surgery unit-HUCA; ICU, intensive care unit-HUCA; RU, reanimation unit-HUCA; PCC, primary-care center; EU, emergency unit-HUCA; GU, geriatric unit of a long-term care facility; HUCA, Hospital Universitario Central de Asturias. ^dAMP, ampicillin; AMC, amoxicillin-clavulanic acid; FOX, cefoxitin; CTX, cefotaxime; ETP, ertapenem; IMP, imipenem; MER, meropenem; CHL, chloramphenicol, AMK, amikacin; GEN, gentamicin; KAN, kanamycin; TOB, tobramycin; STR, streptomycin, ERY, erythromycin; NAL, nalidixic acid; CIP, ciprofloxacin; SUL, sulfonamides; TMP, trimethoprim; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; I, intermediate resistance. ^eAll resistance genes were in silico determined; bla _CTX-M-15 and bla _OXA-48 were also experimentally detected by PCR amplification. Plasmid genes are underlined (see Table 2 for details). ^fST, sequence type according to Achtman; PST, sequence type according to the Pasteur Institute. ^gThe virotype was determined by PCR based on the presence or absence of 13 virulence genes³³; nt, not typeable; na, not applicable. ^hIsolates partially characterized in a previous study¹⁵. ⁱMIC of erythromycin: 256 µg/ml, higher than that obtained for isolates lacking mph(A): 128 µg/ml (Ec-HUCA 3, Ec-HUCA 5, Ec-HUCA 6, Ec-HUCA 7) or 64 µg/ml (Ec-HUCA 4).

Search